[
  {
    "ts": null,
    "headline": "Exxon and 15 More ‘Quality’ Stocks to Own for a Volatile Market",
    "summary": "The market has staged an impressive rebound, but is in for more volatility.  The overarching up-and-down dynamic starts with the fact that sellers have been coming in near the market’s highs to knock stock prices lower because investors and traders know that the more artificial-intelligence spending happens today, the greater the likelihood that the spending will collapse tomorrow.  The  Cboe  Volatility Index, which shows the magnitude of expected swings in stock prices, hit 18 early Monday, down from about 26 in mid November but above its low for the year of about 14.",
    "url": "https://finnhub.io/api/news?id=4fc2e9a58060754fb4a5298fd03ae6e73611b6a37a90ab2e330d1e3e5699017a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764616920,
      "headline": "Exxon and 15 More ‘Quality’ Stocks to Own for a Volatile Market",
      "id": 137658860,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The market has staged an impressive rebound, but is in for more volatility.  The overarching up-and-down dynamic starts with the fact that sellers have been coming in near the market’s highs to knock stock prices lower because investors and traders know that the more artificial-intelligence spending happens today, the greater the likelihood that the spending will collapse tomorrow.  The  Cboe  Volatility Index, which shows the magnitude of expected swings in stock prices, hit 18 early Monday, down from about 26 in mid November but above its low for the year of about 14.",
      "url": "https://finnhub.io/api/news?id=4fc2e9a58060754fb4a5298fd03ae6e73611b6a37a90ab2e330d1e3e5699017a"
    }
  },
  {
    "ts": null,
    "headline": "Time to Shore Up Your Personal Portfolio With These 3 Bullet-Proof Blue-Chip Stocks",
    "summary": "There are a number of valid reasons why many investors may be souring on the ability of equity markets to continue to rise at a 20%+ rate in the years to come. Indeed, it’s been an impressive run for investors in the stock market in recent years, with such outsized gains becoming the norm. That’s ... Time to Shore Up Your Personal Portfolio With These 3 Bullet-Proof Blue-Chip Stocks",
    "url": "https://finnhub.io/api/news?id=c02dbc282f925ae0785bd7b85ce983d1f075ffa11d90aa77c9b816fe3bf53d39",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764616581,
      "headline": "Time to Shore Up Your Personal Portfolio With These 3 Bullet-Proof Blue-Chip Stocks",
      "id": 137658861,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "There are a number of valid reasons why many investors may be souring on the ability of equity markets to continue to rise at a 20%+ rate in the years to come. Indeed, it’s been an impressive run for investors in the stock market in recent years, with such outsized gains becoming the norm. That’s ... Time to Shore Up Your Personal Portfolio With These 3 Bullet-Proof Blue-Chip Stocks",
      "url": "https://finnhub.io/api/news?id=c02dbc282f925ae0785bd7b85ce983d1f075ffa11d90aa77c9b816fe3bf53d39"
    }
  },
  {
    "ts": null,
    "headline": "Take the Zacks Approach to Beat the Markets: MBX Biosciences, Garrett Motion & Monster Beverage in Focus",
    "summary": "MBX Biosciences' sharp rally highlights how Zacks' stock recommendations outpaced broader market gains across multiple portfolios.",
    "url": "https://finnhub.io/api/news?id=ad06617f104f79e937eaa184afecb8a8f91f4e2e4c7ab0e0f64182a468e77f04",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764598800,
      "headline": "Take the Zacks Approach to Beat the Markets: MBX Biosciences, Garrett Motion & Monster Beverage in Focus",
      "id": 137658463,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "MBX Biosciences' sharp rally highlights how Zacks' stock recommendations outpaced broader market gains across multiple portfolios.",
      "url": "https://finnhub.io/api/news?id=ad06617f104f79e937eaa184afecb8a8f91f4e2e4c7ab0e0f64182a468e77f04"
    }
  },
  {
    "ts": null,
    "headline": "National Veterinary Associates Appoints Leslie Storms as President, Ethos Veterinary Health",
    "summary": "National Veterinary Associates (NVA) today announced that Leslie Storms has been appointed President, Ethos Veterinary Health, effective immediately. She will also become an investor in the company. Ethos Veterinary Health is NVA's premier network of specialty and emergency care, comprised of over 140 hospitals and 1,500 team members across North America.",
    "url": "https://finnhub.io/api/news?id=fce7fbed0def8c3f7374037a315862a947659e2de8b6b357ed5301b1a91c1d9f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764597600,
      "headline": "National Veterinary Associates Appoints Leslie Storms as President, Ethos Veterinary Health",
      "id": 137658863,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "National Veterinary Associates (NVA) today announced that Leslie Storms has been appointed President, Ethos Veterinary Health, effective immediately. She will also become an investor in the company. Ethos Veterinary Health is NVA's premier network of specialty and emergency care, comprised of over 140 hospitals and 1,500 team members across North America.",
      "url": "https://finnhub.io/api/news?id=fce7fbed0def8c3f7374037a315862a947659e2de8b6b357ed5301b1a91c1d9f"
    }
  },
  {
    "ts": null,
    "headline": "American Century Value Fund Q3 2025 Contributors/Detractors And Notable Trades",
    "summary": "Shares of Teradyne advanced sharply as investors cheered the companyâs robust earnings and outlook for Teradyneâs artificial intelligence compute testing business. Read more here.",
    "url": "https://finnhub.io/api/news?id=06054e5850a5f2f7dc2e8efa4a56a8952bbee00a1f76fae37494a77a45183957",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764596160,
      "headline": "American Century Value Fund Q3 2025 Contributors/Detractors And Notable Trades",
      "id": 137654794,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1359131126/image_1359131126.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Shares of Teradyne advanced sharply as investors cheered the companyâs robust earnings and outlook for Teradyneâs artificial intelligence compute testing business. Read more here.",
      "url": "https://finnhub.io/api/news?id=06054e5850a5f2f7dc2e8efa4a56a8952bbee00a1f76fae37494a77a45183957"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson receives European Commission approval of IMAAVY® (nipocalimab), a new FcRn blocker offering sustained disease control in a broad population of people living with generalised myasthenia gravis (gMG)",
    "summary": "Nipocalimab is the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are anti-AChR or anti-MuSK antibody-positive In the pivotal Phase 3 Vivacity-MG3 and Phase 2/3 Vibrance-MG studies over 24 weeks, nipocalimab demonstrated rapid and substantial reduction in immunoglobulin G levels, one of the root causes of gMG gMG patients taking nipocalimab demonstrated up to 20 months of sustained disease control and symptom relief in the Vivacity-MG3 study and ongoi",
    "url": "https://finnhub.io/api/news?id=20353a487146f4ff2dc2bdac37ef46817243a37a59704e5cb6fadd597b923133",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764595080,
      "headline": "Johnson & Johnson receives European Commission approval of IMAAVY® (nipocalimab), a new FcRn blocker offering sustained disease control in a broad population of people living with generalised myasthenia gravis (gMG)",
      "id": 137658864,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Nipocalimab is the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are anti-AChR or anti-MuSK antibody-positive In the pivotal Phase 3 Vivacity-MG3 and Phase 2/3 Vibrance-MG studies over 24 weeks, nipocalimab demonstrated rapid and substantial reduction in immunoglobulin G levels, one of the root causes of gMG gMG patients taking nipocalimab demonstrated up to 20 months of sustained disease control and symptom relief in the Vivacity-MG3 study and ongoi",
      "url": "https://finnhub.io/api/news?id=20353a487146f4ff2dc2bdac37ef46817243a37a59704e5cb6fadd597b923133"
    }
  },
  {
    "ts": null,
    "headline": "J&J’s US orthopedic leader leaves amid DePuy spinout process",
    "summary": "Leslie Storms started a new role on Monday as president of Ethos Veterinary Health.",
    "url": "https://finnhub.io/api/news?id=917f42dc473c757774f44c3a293cdea918884303dfca3e128688aec7a2daf806",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764583200,
      "headline": "J&J’s US orthopedic leader leaves amid DePuy spinout process",
      "id": 137658865,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Leslie Storms started a new role on Monday as president of Ethos Veterinary Health.",
      "url": "https://finnhub.io/api/news?id=917f42dc473c757774f44c3a293cdea918884303dfca3e128688aec7a2daf806"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie: Increased Outlook For 2025 And Expansions Merit Continued \"Strong Buy\" Rating",
    "summary": "Discover why AbbVie (ABBV) is a strong buy with expanding immunology, neuroscience, and oncology pipelines.",
    "url": "https://finnhub.io/api/news?id=cd344b45351b5568fb3d4c58324967399568fd6ee1adbe6e67322c5ec346dc6d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764568505,
      "headline": "AbbVie: Increased Outlook For 2025 And Expansions Merit Continued \"Strong Buy\" Rating",
      "id": 137651736,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2247731311/image_2247731311.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Discover why AbbVie (ABBV) is a strong buy with expanding immunology, neuroscience, and oncology pipelines.",
      "url": "https://finnhub.io/api/news?id=cd344b45351b5568fb3d4c58324967399568fd6ee1adbe6e67322c5ec346dc6d"
    }
  }
]